Dermaliq Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Dermaliq Therapeutics, Inc. - overview
Established
2021
Location
Wilmington, DE, US
Primary Industry
Pharmaceuticals
About
Founded in 2021 and based in Delaware, US, Dermaliq Therapeutics, Inc. is a spin-off from Novaliq GmbH that operates as a pharmaceutical company that develops skincare therapies for patients with skin disease. In January 2022, Frank Löscher was appointed as CEO and president of the company, and Dermaliq Therapeutics, Inc. raised USD 15 million in Series A funding led by 3E Bioventures Capital and Beijing Whale Technology Corporation.
The company develops the next generation of skincare therapies to enhance targeted penetration into skin tissues and to reduce unwanted side effects for millions of patients. The technology is called hyliQ™, is designed to allow cutaneous drug delivery with unmatched bioavailability. The technology enables the development of liquid drug products with cosmetic properties. The organization plans to use the January 2022 funding for three Phase 1/2a clinical development programs in dermatology.
Current Investors
3E Bioventures Capital, Beijing Whale Technology Corporation
Primary Industry
Pharmaceuticals
Sub Industries
Beauty & Hygiene, Pharmaceutical Research & Development
Website
www.dermaliq.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Dermaliq Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.